Veracyte’s Q4 non-GAAP EPS rose 47% year-over-year, while revenue grew 18.5%, both figures ahead of analyst forecasts. The top-line gain reflects higher test volumes across its genomic diagnostics portfolio, particularly in thyroid and pulmonology markets.

Improved operating leverage lifted adjusted profit margins by notable basis points, enhancing overall profitability. Investors reacted positively, driving the stock higher in after-hours trading following the release of results.